EN | RU
EN | RU

Help Support

Back

The new formulation of Adalimumab showed more promising treatment outcomes in Rheumatoid Arthritis patients

The new formulation of Adalimumab showed more promising treatment outcomes in Rheumatoid Arthritis patients The new formulation of Adalimumab showed more promising treatment outcomes in Rheumatoid Arthritis patients
The new formulation of Adalimumab showed more promising treatment outcomes in Rheumatoid Arthritis patients The new formulation of Adalimumab showed more promising treatment outcomes in Rheumatoid Arthritis patients

What's new?

The new modified formulation of Adalimumab was found to be effective in reducing overall pain and pain at needle insertion or drug injection in rheumatoid arthritis patients, founds the latest study.

According to a recent analysis by Tomohiko Yoshida and colleagues, the latest formulation of Adalimumab significantly reduces the RA burden, enhances the treatment's adherence quality, less pain during needle insertion and improves the treatment outcomes. Adalimumab is a TNF-alpha blocker delivered via subcutaneous injection. However, the drug is associated with the risk of serious infections and pain at the injection site. This study involved the optimization of a change in the existing Adalimumab on pain, outcomes and treatment outcomes.

The injection pain was divided into four sections; overall pain, pain during drug injection, pain 10 min after injection and pain at needle insertion. The visual analog scale was used to determine the impact of the modification to the current formulation on pain.  The influence of the change in injection pain intensity on treatment motivation was measured using faces pain scale.
Lower scores of overall pain (1.6 vs. 6.7),  pain during injection (1.6 vs. 7.0), pain 10 min after the injection (0.4 vs. 3.1) and pain at needle insertion (1.8 vs. 4.7) was obtained with new formulation than current formulation.

All outcomes displayed a considerable difference (p < 0.001). Paired t-tests were applied as well. Injection pain with influenza vaccine and the present formulation were reported by 68% and 80% of the patients, respectively. Although, the ratio of the patients who felt pain with the new Adalimumab reduced to 20%.

Source:

Modern Rheumatology

Article:

New Adalimumab formulation associated with less injection site pain and improved motivation for treatment

Authors:

Tomohiko Yoshida et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en
Try: